<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126189">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459666</url>
  </required_header>
  <id_info>
    <org_study_id>Mann-Cohen Version 2</org_study_id>
    <nct_id>NCT01459666</nct_id>
  </id_info>
  <brief_title>Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer</brief_title>
  <official_title>A Prospective, Dual-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of abobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AboutSkin Dermatology and DermSurgery, PC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medicis Pharmaceutical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AboutSkin Dermatology and DermSurgery, PC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of using aboBTX-A to improve wound healing prior to Mohs
      micrographic surgery and reconstruction for skin cancer of the forehead
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Outcomes by the Patient and Observer Assessment Scale (POSAS), Visual Analog Scale, and
           Patient Satisfaction Survey.

        -  Study consists of 5 clinic visits over approximately 6 months
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient and Observer Assessment Scale (POSAS)</measure>
    <time_frame>6 months</time_frame>
    <description>The Patient and Observer Scar Assessment Scale (POSAS) consists of two numeric scales. One scale is completed by the patients, the other by the clinician. This scale is different than previous scales because it takes the patient's input into consideration. It has good internal consistency and interobserver reliability. The assessment will take place at Day 0, Week 1, Week 6, and Month 6.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Scar</condition>
  <arm_group>
    <arm_group_label>Dysport (abobotulinumtoxinA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dysport (abobotulinumtoxinA)</intervention_name>
    <description>Intramuscular injection effects lasting up to 3 months</description>
    <arm_group_label>Dysport (abobotulinumtoxinA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacteriostatic 0.9% Sodium Chloride (vehicle)</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have biopsy proven skin cancer on the forehead that is amenable to Mohs surgery

          -  Undergoing elective reconstruction of biopsy proven skin cancer that is amenable to
             Mohs surgery with defect size measuring 1.0 cm or greater

          -  If female, not currently pregnant, not currently breastfeeding, no potential for
             pregnancy, or if of child-bearing age, agrees to using birth control.

          -  Agrees to not use disallowed concomitant medications (retinoids) and agrees to use
             sunscreen in the forehead area for the duration of the study

        Exclusion Criteria:

          -  Current or past history of a neuromuscular disease (such as myasthenia gravis,
             amyotrophic lateral sclerosis, Eaton-Lambert syndrome)

          -  History of radiation therapy or chemotherapy

          -  History of keloid or other hypertrophic scar formation

          -  Has used botulinum toxin in the forehead area within one year.

          -  Has used any topical retinoids to the forehead area within the past 4 weeks

          -  Any hypersensitivity to any component of abobotulinumtoxinA (i.e. cow milk protein)
             or any previous hypersensitivity to any botulinum toxin A or related product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Mann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel L Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>About Skin Dermatology and Dermsurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Sussman</last_name>
    <phone>303-756-7546</phone>
    <email>research@aboutskinderm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AboutSkin Dermatology and DermSurgery</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Sussman</last_name>
      <phone>303-756-7546</phone>
      <email>research@aboutskinderm.com</email>
    </contact>
    <investigator>
      <last_name>Joel L Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine: Department of Dermatology</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Doud, CCRP</last_name>
      <phone>216-983-0861</phone>
      <email>kristen.doud@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Margaret Mann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>January 17, 2012</lastchanged_date>
  <firstreceived_date>October 18, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AboutSkin Dermatology and DermSurgery, PC</investigator_affiliation>
    <investigator_full_name>AboutSkin Dermatology</investigator_full_name>
    <investigator_title>Principal Investigator, Director at AboutSkin Dermatology</investigator_title>
  </responsible_party>
  <keyword>Scar</keyword>
  <keyword>Forehead</keyword>
  <keyword>Skin Cancer</keyword>
  <keyword>MOHS Surgery</keyword>
  <keyword>Dermatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
